102. Jahresversammlung Der SGDV Réunion Annuelle

Total Page:16

File Type:pdf, Size:1020Kb

102. Jahresversammlung Der SGDV Réunion Annuelle AOÛT 2020 VOLUME 32 - N° 6 Zürich Live Stream Podcast 17 - 18 September 2020 Wissenschaftliches Programm SGDV Programme scientifique SSDV 102. Seite/Page 4 Traktandenliste SGDV Jahresversammlung Ordre du jour SSDV der SGDV Seite/Page 22 Freie Mitteilungen 102ème Communications libres Réunion annuelle Seite/Page 24 Posters de la SSDV Seite/Page 30 Dieses Heft wrde für die Fortbildung der Schweizer Dermatologen dank einer Hilfe die folgenden Firmen realisiert: Ce numéro a été réalisé grâce à une aide pour la formation continue des dermatologues suisses des firmes : Jetzt kassen- zulässig! * bei atopischer Durchbruch Dermatitis** Doppelt stark.1 Schnell.2 Einfach.3 QR­Code scannen und weitere Informationen zu einer Behandlung mit DUPIXENT® erhalten Doppelt stark. Wirkung auf Juckreiz & Hautbild.1 NEU Schnell. Signifikante Symptombesserung innerhalb 2 Wochen.2 Einfach. Alle 2 Wochen subkutan (s.c.) & ohne Monitoring.3 ** DUPIXENT®: Erstes Biologikum bei erwachsenen Patienten mit mittelschwerer bis schwerer atopischer Dermatitis*** * FDA Press Release. FDA approves new eczema drug Dupixent. March 28, 2017. www.fda.gov. *** Wenn eine Therapie mit verschreibungspflichtigen topischen Medika­ menten keine angemessene Krankheitskontrolle ermöglicht oder nicht empfohlen wird. DUPIXENT® kann mit oder ohne topische Kortikosteroide verwendet werden.3 1 Simpson EL et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016; 375: 2335–48; 2 Blauvelt A et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287–303; 3 DUPIXENT® Fachin- formation, Stand April 2019, www.swissmedicinfo.ch. Dupixent® Injektionslösung (300mg/2ml) W: Dupilumab (aus gentechnisch veränderten Zellen des chinesischen Hamsters). I: Mittelschwerer bis schwerer atopischer Dermatitis (AD) bei erwach- senen Patienten, bei denen die Erkrankung durch verschreibungspflichtige topische Präparate unzureichend kontrolliert ist, oder diese Präparate nicht indiziert sind. Dupixent kann mit oder ohne topische Kortikosteroide angewendet werden. Dosierung: Anfangsdosis von 600 mg als subkutane Injektion (zwei Injektionen zu je 300 mg), danach 300 mg als subkutane Injektion alle zwei Wochen. Niereninsuffizienz gleiche Dosierung. KI: Darf nicht gegeben werden bei Überempfindlichkeit gegen Wirkstoff oder einen Hilfsstoff. Sch/S: Keine Anwendung in der Schwanger- schaft, es sei denn der potenzielle Nutzen übersteigt das potenzielle Risiko für den Fötus. VM: Enthält Natrium. Überempfindlichkeitsreaktionen: Anwendung sofort beenden und eine geeignete Behandlung einleiten. Helminthose: Vorbestehende Helminthose vor Therapie mit Dupixent behandeln, bei Infektion während der Behandlung und Nichtansprechen auf Helminthosebehand- lung Dupixent aussetzen bis Infektion abgeklungen ist. Konjunktivitis und Keratitis: Patienten darauf hinweisen, dass sie das Auftreten oder eine Verschlimmerung von Augensymptomen dem Arzt / der Ärztin mitteilen sollten. Komorbides Asthma: Anpassung der Asthma-Behandlung nicht ohne vorherige Absprache mit Arzt / Ärztin, nach dem Absetzen der Behandlung diese Patienten sorgfältig überwachen. IA: Anwendung von Lebendimpfstoffen vermeiden. UW: Sehr häufig: Reaktionen an der Injektionsstelle (9,6 %). Häufig: Konjunktivitis, Augenjucken; Blepharitis, oraler Herpes, Eosinophilie, Kopfschmerzen. P: Dupixent 300 mg, Injektionslösung in einer Fertigspritze: Packung mit 2 Fertigspritzen mit Sicherheitssystem. AK: B. ZI: sanofi-aventis (schweiz) ag, MAT-CH-2000940 1214 Vernier/GE (für weitere Informationen vgl. http://www.swissmedicinfo.ch/). Stand der Information: April 2019 (SACH.DUP.19.04.0253(1)). Sanofi und Regeneron arbeiten gemeinsam an einem globalen Produktentwicklungsprogramm und an der Vermarktung von DUPIXENT® Kontakt: Sanofi Genzyme · [email protected] · www.sanofigenzyme.ch Zulassungsinhaberin: sanofi-aventis (schweiz) ag · 3, route de Montfleury · 1214 Vernier 151057_DUP_CH_Anzeige_DE_Final.indd 1 04.06.20 17:31 RUBRIKEN DER DERMATOLOGICA HELVETICA – RUBRIQUES DE DERMATOLOGICA HELVETICA Weiterbildung - Formation continue Jetzt DH Redaktionsbüro, Bureau éditorial: JH Saurat: Chefredaktor, Editeur en chef DERMATOLOGICA HELVETICA M Harms: Chefredaktor StV, Editeur en chef adjointe kassen- Août 2020 - Volume 32 - N° 6 A Navarini: Assoziierter Redaktor, Rédacteur associé Carine Herreras ([email protected]): Redaktionsbüro, Bureau éditorial zulässig! Atar Roto Presse SA, Genève: Druck, Impression SOMMAIRE Sektionen, Sections: JH Saurat: Journal Club, Focus * bei atopischer Chefärzte, Médecins chef-de-service/D. Hohl: Case reports, coups d’œil (Koor- ** 5 Grussworte – Messages de bienvenue dination: Redaktionsbüro, Coordination: Bureau rédactionel, C Herreras, derm.helv@ Durchbruch bluewin.ch) Dermatitis 10 Wissenschaftliches Programm SGDV – A Navarini: Peer-reviewed contributions A Navarini: Weiterbildung der Assistenzärzte, Formation post-graduée des Programme scientifique SSDV assistants M Harms/J. Hafner: Das diagnostische Photo, Photo du mois, terminologie 22 Traktandenliste SGDV – C Mainetti/D Hohl: Tribune des Präsidenten, Tribune du président 1 M Tomasik: Neues aus dem Generalsekretariat, Nouvelles du secrétariat général Doppelt stark. N Griesser: Neue Mitglieder, Nouveaux membres 2 3 Ordre du jour SSDV – Neues aus den kantonalen Dermatologengesellschaften, den Kommissionen Schnell. Einfach. und Arbeitsgruppen, Nouvelles des sociétés cantonales de dermatologie et 24 Freie Mitteilungen vénéréologie, des commissions et des groupes de travail (Koordination: Redak- tionsbüro, Coordination: Bureau éditorial, C Herreras, [email protected]) Communications libres J Hafner: Neues aus der Industrie, Nouvelles de l’industrie (Koordination: Redak- tionsbüro, Coordination: Bureau éditorial, C Herreras, [email protected]) 30 Posters Ständige Kommission für Kommunikation, Commission permanente pour la communication: AK Lapointe, AM Skaria: Redaktoren Westschweiz, Editeurs députés pour la Suisse romande E Bianchi, F Pelloni: Redaktoren Tessin, Editeurs députés pour le Tessin B Schlagenhauff, J Hafner: Redaktoren deutsch-sprachige Schweiz, Editeurs députés pour la Suisse alémanique e-mail: [email protected] Authors instructions (peer reviews) ISSN: 1420-2360 Size: Papers should comprise approximately 700-2000 words including figures, tables and references. Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head. Full address: The exact postal address of the corresponding author complete with postal code must be given. Key words: For indexing purposes, a list of 3–5 key words in English is essential for all papers. Abstract: Normally each paper needs an abstract of not more than 150 words. It should contain the following information: purpose of the study, procedures, results, conclusions and message of the paper. Abstracts submitted for publication in the section Original Papers should be structured as follows: Background: What is the major problem that prompted the study • Objective: What is the purpose of the study? • Methods: How was the study performed? Results: Most important findings? QR­Code scannen und • Conclusion: Most important conclusion? weitere Informationen Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page. Formatting rules: ANZEIGENREGIE – RÉGIE DES ANNONCES zu einer Behandlung mit • Do not use any special page layout. If you would like to see what your manuscript looks like with embedded tables and illustrati- ® ons, remember that we need text and illustrations as separate files! DUPIXENT erhalten • Enter your text continuously flush left. Do not use hard returns ("enter") within a paragraph, only at its end. • Do not use footer and header functions. • Use boldface and italics as well as sub- and superscript where appropriate. Carine HERRERAS • Use your word-processing program to insert Greek letters, mathematical symbols, etc. Legends: The legends to your figures are part of the text and should be listed at the end of your text file. Tél. +41 79 667 32 48 Line Drawings Black and White Half-Tone Images, Color Illustrations E-mail: [email protected] Doppelt stark. Wirkung auf Juckreiz & Hautbild.1 Scans • For processing and retouching scanned half-tone images, Photoshop is recommended. Please save the original scan as well as your processed version. 2 • Export black and white half-tones and color illustrations as TIF or EPS format, as close as possible to their anticipated size in print. Schnell. Signifikante Symptombesserung innerhalb 2 Wochen. • Save them as separate files, not embedded in the text. ÉDITION NEU • Scanned line drawings must be digitalized with a resolution of at least 800, better 1000 dpi (dots per inch) after scaling. 3 • Scanned half-tone images should be digitalized with a final resolution of 300 dpi, a 12 bit grayscale accuracy and a density range Dermatologica Helvetica Einfach. Alle 2 Wochen subkutan (s.c.) & ohne Monitoring. of 2.8. Screen values must lie between 5% and 95%. • Scanned color illustrations must be digitalized in RGB mode with a resolution of at least 300 dpi, a 32 bit accuracy and a density JH Saurat range of 2.8. • Summary. 22, rue de l’Athénée Make sure that your original has the resolution values in this
Recommended publications
  • September-Sunshine-Line-2021
    The Sunshine 186 Main St STE 2 * Brookville, PA 15825 Phone:(814) 849-3096 1-800-852-8036 Line www.jcaaa.org Find us on Facebook: @JeffersonCountyAAA Want to receive our newsletter by email? Volume 7 Issue 9 September 2021 Register on our website or call us! FREE Community Workshop Presentation: Get Ready for Medicare: The Basics for People Who are Joining Already r Enrolled Jefferson County Area Agency on Aging Medicare Education and Decision Insight Program September 8th 6:00pm-7:00pm Brookville Heritage House September 16th 10:00am-11:00am Punxy Area Senior Center September 17th 11:00am-12:00pm Reynoldsville Foundry Senior Center September 22nd 11:00am-12:00pm Brockway Depot Senior Center Call Mindy at 814-849-3096 Ext 232 to sign up What is Medicare Education and Decision Insight (PA-MEDI) Medicare Education and Decision Insight (PA MEDI) is the State Health Insurance Assistance Program in Pennsylvania. We provide free, unbiased insurance counseling to people on Medicare. PA MEDI counselors are specifically trained to answer any questions about your coverage.We provide you with clear, easy to understand information about your Medicare options and can assist in comparing plans. We will also screen you to see if you qualify for any financial assistance programs to get help paying for your prescription drugs or Part B premium. You will have a better understanding of: • Medicare • Part A, B and C • An Advantage Plan • Savings programs • How to avoid penalties • And much more 2 September 2021 Pennsylvania 211: Get Connected. Get Help. ™ If you need to connect with resources in your community, but don’t know where to look, PA 211 is a great place to start.
    [Show full text]
  • Dermatologic Findings in 16 Patients with Cockayne Syndrome and Cerebro-Oculo-Facial-Skeletal Syndrome
    Research Case Report/Case Series Dermatologic Findings in 16 Patients With Cockayne Syndrome and Cerebro-Oculo-Facial-Skeletal Syndrome Eric Frouin, MD; Vincent Laugel, MD, PhD; Myriam Durand, MSc; Hélène Dollfus, MD, PhD; Dan Lipsker, MD, PhD Supplemental content at IMPORTANCE Cockayne syndrome (CS) and cerebro-oculo-facial-skeletal (COFS) syndrome jamadermatology.com are autosomal recessive diseases that belong to the family of nucleotide excision repair disorders. Our aim was to describe the cutaneous phenotype of patients with these rare diseases. OBSERVATIONS A systematic dermatologic examination of 16 patients included in a European study of CS was performed. The patients were aged 1 to 28 years. Six patients (38%) had mutations in the Cockayne syndrome A (CSA) gene, and the remaining had Cockayne syndrome B (CSB) gene mutations. Fourteen patients were classified clinically as having CS and 2 as having COFS syndrome. Photosensitivity was present in 75% of the patients and was characterized by sunburn after brief sun exposure. Six patients developed symptoms after short sun exposure through a windshield. Six patients had pigmented macules on sun-exposed skin, but none developed a skin neoplasm. Twelve patients (75%) displayed cyanotic acral edema of the extremities. Eight patients had nail dystrophies and 7 had hair anomalies. CONCLUSIONS AND RELEVANCE The dermatologic findings of 16 cases of CS and COFS Author Affiliations: Author syndrome highlight the high prevalence of photosensitivity and hair and nail disorders. affiliations are listed at the end of this Cyanotic acral edema was present in 75% of our patients, a finding not previously reported article. in CS. Corresponding Author: Eric Frouin, MD, Service d’Anatomie et Cytologie Pathologiques, Université de JAMA Dermatol.
    [Show full text]
  • Digital Clubbing
    Review Article Digital clubbing Malay Sarkar, D. M. Mahesh1, Irappa Madabhavi2 Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, 1Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 2Post Graduate Student (Medicine), Indira Gandhi Medical College, Shimla, India ABSTRACT Digital clubbing is an ancient and important clinical signs in medicine. Although clubbed fingers are mostly asymptomatic, it often predicts the presence of some dreaded underlying diseases. Its exact pathogenesis is not known, but platelet‑derived growth factor and vascular endothelial growth factor are recently incriminated in its causation. The association of digital clubbing with various disease processes and its clinical implications are discussed in this review. KEY WORDS: Cancer, digital clubbing, hypertrophic osteoarthropathy, megakaryocytes, vascular endothelial growth factor Address for correspondence: Dr. Malay Sarkar, Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla ‑ 171 001, India. E‑mail: [email protected] INTRODUCTION long bones and occasional painful joint enlargement. It was initially known as hypertrophic pulmonary Digital clubbing is characterized by a focal bulbous osteoarthropathy (HPOA) based on the fact that majority enlargement of the terminal segments of the fingers of cases of HOA are due to malignant thoracic tumors. and/or toes due to proliferation of connective tissue The term “pulmonary” was later abandoned as it was between nail matrix and the distal phalanx. It results in realized that the skeletal syndrome may occur in several increase in both anteroposterior and lateral diameter of non‑pulmonary diseases and even may occur without the nails.[1] Clubbed fingers are also known as watch‑glass any underlying illness.
    [Show full text]
  • Sarcoidosis Mimicking Lipodermatosclerosis
    Sarcoidosis Mimicking Lipodermatosclerosis Carol L. Huang, MD; Diya F. Mutasim, MD The clinical presentation of cutaneous sarcoidosis We describe the case of a woman who presented is highly variable. Rare presentations include with unilateral ulcerating sarcoidosis of the lower leg ulcerated plaques, morpheaform lesions, and uni- with progressive fibrosis and edema mimicking lipo- lateral lower extremity edema. We report the dermatosclerosis. The presentation is unique in that case of a woman who presented with unilateral the patient exhibited all 3 of the rare manifestations ulcerating sarcoidosis of the lower leg with pro- of sarcoidosis (ulceration, unilateral edema, and fibro- gressive fibrosis and edema mimicking lipoder- sis), with morphologic similarity to lipodermato- matosclerosis. This case is unique in that the sclerosis. To our knowledge, this unique presentation patient exhibited all 3 of the rare manifestations of has not been previously reported in the literature. sarcoidosis; to our knowledge, this presentation has not been previously reported in the literature. Case Report Cutis. 2005;75:322-324. A 52-year-old African American woman with a 5-year history of a slowly enlarging lesion on the left lower leg reported tenderness, swelling, and ystemic sarcoidosis is a chronic granulomatous burning in the area. She had a history of pulmonary disease that involves the skin in 25% of sarcoidosis, and the diagnosis was confirmed by S affected patients. The clinical presentation of results of transbronchial biopsy; she had been taking cutaneous sarcoidosis is variable and includes both prednisone 20 to 40 mg/d for the pulmonary sar- specific and nonspecific lesions. Specific lesions coidosis.
    [Show full text]
  • 58 Yo Woman Referred for Unresponsive Drug Rash • Review Treatment Options
    12:50 - 1:50pm Disclosures Can't Miss Dermatology Diagnoses: The following relationships exist related to this presentation: Cutaneous Manifestations of ► Daniela Kroshinsky, MD MPH: No financial relationships to disclose. Systemic Disease SPEAKER Daniela Kroshinsky, MD MPH Off-Label/Investigational Discussion ► In accordance with pmiCME policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Overview • Identify cutaneous manifestations of systemic disease and their associated risk factors 58 yo woman referred for unresponsive drug rash • Review treatment options • Learn other mimicking cutaneous conditions Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes. Dermatomyositis • Ragged cuticles, nail fold telangiectasias • Extensor limb rash, including knuckles • Shawl‐distribution poikiloderma with extension into scalp • Periorbital edema, heliotrope rash • Diffuse facial erythema, malar erythema • Holster sign • More violaceous and pruritic than lupus • Erosions, ulcerations Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes. Forms • Resembles polymyositis; symmetric proximal muscles usually • Skin findings precede muscle in most cases • Classic (with muscle disease) • Amyopathic (myositis may evolve over time) • Hypomyopathic dermatomyositis (no clinical muscle weakness, but myositis present on radiographic or laboratory
    [Show full text]
  • Nails in Systemic Disease
    CME: DERMATOLOGY Clinical Medicine 2021 Vol 21, No 3: 166–9 Nails in systemic disease Authors: Charlotte E GollinsA and David de BerkerB A change in colour, size, shape or texture of finger- and MatrixCuticle toenails can be an indicator of underlying systemic disease. Nail plate An appreciation of these nail signs, and an ability to interpret them when found, can help guide diagnosis and management Nail bed of a general medical patient. This article discusses some ABSTRACT common, and some more rare, nail changes associated with systemic disease. Proximal nail fold Introduction Cuticle Examination of nails is a skill that, although emphasised when Matrix (lunula) revising for general medical exams, can be overlooked in day- Nail plate Lateral nail fold to-day practice. The value of noticing, understanding and Onychocorneal interpreting nail changes can positively add to clinical practice as band these signs can provide valuable clues to a diagnosis. Here we present a brief overview of selected common and rarer Fig 1. Anatomy of the nail plate. nail abnormalities associated with systemic conditions, as well as a limited explanation of the pathophysiology of some of the changes. Anatomy of the nail unit located in the distal third of the nail plate. They are caused The nail unit (Fig 1) is an epithelial skin appendage composed by damage to capillaries within the nail bed, which have a of the hardened nail plate surrounded by specialised epithelial longitudinal orientation, leading to their linear appearance. In the surfaces that contribute to its growth and maintenance.1 The nail case of bacterial endocarditis, this damage is likely to be caused by plate is formed of keratinised epithelial cells.
    [Show full text]
  • Prostaglandin E2 Increase in Pachydermoperiostosis Without 15-Hydroprostaglandin Dehydrogenase Mutations
    118 Letters to the Editor Prostaglandin E2 Increase in Pachydermoperiostosis Without 15-hydroprostaglandin Dehydrogenase Mutations Kyoko Nakahigashi1, Atsushi Otsuka1*, Hiromi Doi1, Satsuki Tanaka2, Yoshiaki Okajima3, Hironori Niizeki4, Asami Hiraki- yama4, Yoshiki Miyachi1 and Kenji Kabashima1* 1Department of Dermatology, Kyoto University, Graduate School of Medicine, 54 Shogoin-Kawara, Sakyo, Kyoto 606-8507, 2Department of Diabetes and Endocrinology, and 3Department of Orthopedic Surgery, Osaka Saiseikai Nakatsu Hospital, Osaka, and 4Department of Dermatology, National Center for Child Health and Development, Tokyo, Japan. *E-mails: [email protected], [email protected] Accepted April 10, 2012. Pachydermoperiostosis (PDP), a form of primary hyper­ head, and marked clubbing of the fingers (Fig. 1a, b). trophic osteoarthropathy (PHO), is a rare hereditary No other remarkable physical findings were observed, disease diagnosed by the presence of the triad of digital and he did not present seborrhoea, acne, folliculitis or clubbing, periostosis, and pachydermia (1, 2). Elevated hyperhidrosis. Family history was non-contributory. prostaglandin E2 (PGE2) levels with cytokine­mediated All laboratory tests including serum levels of growth tissue remodelling and vascular stimulation may underlie hormone, insulin­like growth factor­1, thyroid fun­ PHO and is associated with the features such as hyper­ ction, immunoglobulins, haemoglobin A1c, and bone hidrosis, acroosteolysis, pachydermia, periostosis and mineral metabolism were within normal ranges, which arthritis (3). Homozygous and compound heterozygous ruled out thyroid acropathy and acromegaly. Magnetic germline mutations in the 15­hydroxyprostaglandin resonance imaging of the head revealed cutis verticis dehydrogenase (HPGD) gene encoding the major PGE2 gyrate (Fig. 1c). X-ray examination of the knee region catabolizing enzyme have been described in familial PHO revealed periostosis with cortical thickening and ec­ cases (4).
    [Show full text]
  • FINGERNAIL and TONGUE ANALYSIS Heart, Hormones and Cancer
    FINGERNAIL AND TONGUE ANALYSIS Heart, Hormones and Cancer October 3, 2014 – Anchorage, Alaska Tsu-Tsair Chi, NMD, PhD (714) 777-1542 Copyright. Chi’s Enterprise, Inc. Continued Lecture Sunday, October 5, 1:30 pm • Review of Heart and Hormones • Fingernail and Tongue Analysis for Digestion, Liver, Kidneys, Lungs, Mental Health, Skin, Autoimmune Conditions Copyright. Chi’s Enterprise, Inc. CONTACT CHI’S ENTERPRISE, INC. 1435 N. Brasher Street Anaheim, CA 92807 (714) 777-1542 www.chi-health.com Copyright. Chi’s Enterprise, Inc. • 2010 Hardcover edition • Over 120 color pictures Copyright. Chi’s Enterprise, Inc. Jonathan Wright, MD from WA, writing ‘Returning to the Roots of Medicine’ in the preface of Dr. Chi’s Fingernail and Tongue Analysis book: “…the reemergence of interest in ‘hands on’ physical diagnosis together with extensive knowledge of the body systems in health and disease known by the modern physician… Having learned the fingernail and tongue method from the ‘master,’ Dr. Chi, I intend to use it everyday in my practice.” Copyright. Chi’s Enterprise, Inc. D. Williams, MD from GA, suggests that all doctors learn the CHI system for the following reasons: • Make your analysis skills quicker and more effective • Save a lot of clinic time and avoid malpractice • Avoid unnecessary and expensive tests, improve your provider profile • Observe critical health problems earlier • The system is low cost and easy to use Copyright. Chi’s Enterprise, Inc. Cases detected by F& T Analysis (2001- 2013)* Type Cases Cancer 228+ Heart/Bypass 54+ And more… * Later verified by medical tests Copyright. Chi’s Enterprise, Inc. 1,970+ Cases successfully improved by Dr.
    [Show full text]
  • Print This Issue
    August 2021 National Institutes of Health • Department of Health and Human Services • newsinhealth.nih.gov Inside News: 3 Fingernails and Health 4 COVID-19 Vaccine and Variants 4 Heart Inflammation 4 ClinicalTrials.gov Your Body’s Bugs Nurturing Healthy Microbes Microscopic bugs called mi- eczema. They found that it crobes can be found in your improved symptoms, includ- eyes, mouth, gut, skin, and ing itching and rashes. everywhere else. But don’t Your gut hosts lots of mi- be alarmed. Most of your mi- crobes. These can be thrown crobes are useful. They help out of balance by many you digest food. They prevent things, including antibiotics dangerous infections in your and diet. That can make room organs. And so much more. for harmful ones to grow. They’re vital for your health. One especially dangerous This collection of microbes microbe is a type of in your body includes bacte- bacteria that can grow ria, fungi, and viruses. To- in the intestines called gether, it’s called the human Clostridioides difficile. C. microbiome. difficile can cause fatal “The microbiome is just diarrhea, especially in older as important as the brain, adults. It’s often resistant to liver, kidney, or heart,” says treatment. Dr. Eugene Chang, who Researchers have developed studies gut microbes at the Restoring Balance • One of the big a type of treatment for C. difficile in- University of Chicago. jobs for our helpful microbes is to fection called fecal microbial trans- Scientists have cataloged the take up space. They live in places plant. A patient is given microbes types of microbes that live in the in the body that might otherwise from the large intestine of a healthy human body.
    [Show full text]
  • Mutations in the Prostaglandin Transporter SLCO2A1 Cause Primary Hypertrophic Osteoarthropathy with Digital Clubbing
    J Busch et al. SLCO2A1 Mutations Cause Primary Hypertrophic Osteoarthropathy Mutations in the Prostaglandin Transporter SLCO2A1 Cause Primary Hypertrophic Osteoarthropathy with Digital Clubbing Journal of Investigative Dermatology (2012) 132, 2473–2476; doi:10.1038/jid.2012.146; published online 14 June 2012 TO THE EDITOR noids (e.g., PGE2), this transport is in exon 9 (Figure 2). At age 25, he Digital clubbing with enlargement of mediated by the PG carrier SLCO2A1 complained about swelling of fingers the distal phalanges and overcurvature (Kanai et al., 1995). In a second step, and toes, thickening and furrowing of of the nails frequently occurs as a oxidation of prostanoids takes place facial skin, and increasing knee pain, secondary feature of chronic hypoxia within the cell via HPGD. In this study, which did not significantly improve in bronchopulmonary or cardiovascular we hypothesized that PHO can also be despite administration of nonsteroidal disease and systemic inflammatory or caused by mutations in the gene en- anti-inflammatory drugs. Seborrhea was neoplastic processes. Genetic causes coding the PG transporter SLCO2A1. successfully treated with 20 mg per day are much less common, but their SLCO2A1 is located on 3q22, com- isotretinoin. His renal PGE2 clearance decipherment provides a better under- prises 14 exons, and encodes a 643- was considerably increased (731 ng per standing of those more common dis- amino-acid type IV transmembrane hour per 1.73 m2, normal level 4–27), eases. Mutations in the 15-hydroxy- protein that belongs to the solute carrier similar to PGE-M, which showed a high prostaglandin dehydrogenase (HPGD) organic anion transporter family (Lu clearance of 2,960 ng per hour per gene encoding the major prostaglandin and Schuster, 1998).
    [Show full text]
  • Nail Disorders in Older People, and Aspects of Their Pharmaceutical Treatment
    Nail disorders in older people, and aspects of their pharmaceutical treatment Sudaxshina Murdan* UCL School of Pharmacy, 29-39 Brunswick Square, London, WC1N 1AX, UK *Corresponding author T +44-207 753 5810 F +44-207-753-5942 E [email protected] 1 Abstract The aim of this paper was to explore how aging influences the nail unit, its disorders and its response to treatment, and to identify some of the age-related gaps in the ungual drug delivery literature. Aging causes obvious changes to the nail, some of which are inherently due to old age, while others are due to diseases/conditions which become more prevalent as we age. Alterations in the nail plate’s colour, contour, thickness, fragility, surface features, cell size, chemical composition and growth rate are some of the changes, with toenails and fingernails showing different effects. With respect to disease, the incidence of onychomycosis – the most common nail disorder – is considerably higher in older people. Similarly, brittle nails become more common as we age. In contrast, the literature about ageing and the incidence of nail psoriasis is inconclusive, although, it is clear that as one gets older, the negative impact of nail psoriasis on one’s quality of life decreases. Pharmaceutical treatment of the diseases comprises local and systemic therapies, sometimes in combination. Systemic therapies have the inherent disadvantages of adverse systemic effects, drug interactions and the need for monitoring, disadvantages which are especially problematic for older people who are more likely to suffer from co-morbidities and be on other medications. Topical therapy avoids such disadvantages.
    [Show full text]
  • Atlas of DISEASES of the NAIL
    An Atlas of DISEASES OF THE NAIL THE ENCYCLOPEDIA OF VISUAL MEDICINE SERIES An Atlas of DISEASES OF THE NAIL Phoebe Rich, MD Oregon Health Sciences University Portland, Oregon, USA Richard K.Scher, MD College of Physicians and Surgeons Columbia University, New York, USA The Parthenon Publishing Group International Publishers in Medicine, Science & Technology A CRC PRESS COMPANY BOCA RATON LONDON NEW YORK WASHINGTON, D.C. Published in the USA by The Parthenon Publishing Group Inc. 345 Park Avenue South, 10th Floor New York NY 10010 USA This edition published in the Taylor & Francis e-Library, 2005. To purchase your own copy of this or any of Taylor & Francis or Routledge’s collection of thousands of eBooks please go to www.eBookstore.tandf.co.uk. Published in the UK and Europe by The Parthenon Publishing Group 23–25 Blades Court Deodar Road London SW15 2NU UK Copyright © 2003 The Parthenon Publishing Group Library of Congress Cataloging-in-Publication Data Rich, Phoebe An atlas of diseases of the nail/Phoebe Rich, R.K.Scher p.; cm.—(The encyclopedia of visual medicine series) Includes bibliographical references and index. ISBN 1-85070-595-X 1. Nails (Anatomy)—Diseases—Atlases. I. Title: Diseases of the nail. II. Rich, Phoebe III. Title. IV. Series. [DNLM: 1. Nail Diseases—diagnosis—Atlases. 2. Nail Diseases—therapy—Atlases. WR 17 S326a 2002] RL165.S35 2002 616.5′47—dc21 2002025346 British Library Cataloguing in Publication Data Rich, Phoebe— An atlas of diseases of the nail 1. Nails (Anatomy)—Diseases I. Title II. Scher, Richard K., 1929– 616.5′47 ISBN 0-203-49069-X Master e-book ISBN ISBN 0-203-59671-4 (Adobe eReader Format) ISBN 1-85070-595-X (Print Edition) First published in 2003 This edition published in the Taylor & Francis e-Library, 2005.
    [Show full text]